Catalyst Wire Dossier Catalyst Wire Dossier

0.045% tazarotene/0.01% halobetasol lotion

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 0.045% tazarotene/0.01% halobetasol lotion, covering 2023-11-18 to 2023-11-18. Get the full timeline:

Most recent: Clinical Trial Update: Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis [Phase 4]

See pricing